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Abstract
Background: DNA methylation has been linked to genome regulation and dysregulation in health and disease
respectively, and methods for characterizing genomic DNA methylation patterns are rapidly emerging. We have
developed/refined methods for enrichment of methylated genomic fragments using the methyl-binding domain of
the human MBD2 protein (MBD2-MBD) followed by analysis with high-density tiling microarrays. This MBD-chip
approach was used to characterize DNA methylation patterns across all non-repetitive sequences of human
chromosomes 21 and 22 at high-resolution in normal and malignant prostate cells.
Results: Examining this data using computational methods that were designed specifically for DNA methylation tiling
array data revealed widespread methylation of both gene promoter and non-promoter regions in cancer and normal
cells. In addition to identifying several novel cancer hypermethylated 5’ gene upstream regions that mediated
epigenetic gene silencing, we also found several hypermethylated 3’ gene downstream, intragenic and intergenic
regions. The hypermethylated intragenic regions were highly enriched for overlap with intron-exon boundaries,
suggesting a possible role in regulation of alternative transcriptional start sites, exon usage and/or splicing. The
hypermethylated intergenic regions showed significant enrichment for conservation across vertebrate species. A
sampling of these newly identified promoter (ADAMTS1 and SCARF2 genes) and non-promoter (downstream or within
DSCR9, C21orf57 and HLCS genes) hypermethylated regions were effective in distinguishing malignant from normal
prostate tissues and/or cell lines.
Conclusions: Comparison of chromosome-wide DNA methylation patterns in normal and malignant prostate cells
revealed significant methylation of gene-proximal and conserved intergenic sequences. Such analyses can be easily
extended for genome-wide methylation analysis in health and disease.
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Methylation at the 5-position of cytosine in CpG dinucleo-
tides is a key epigenetic process in vertebrate species
where it serves critical roles in normal genome homeosta-
sis, including transcriptional regulation, establishment of
chromatin structure, suppression of repetitive elements,
imprinting, and × chromosome inactivation [1,2]. Further-
more, DNA methylation defects are a hallmark of many
human diseases including cancer [3]. Characterizing DNA
methylation patterns genome-wide and with high-resolu-
tion can yield many insights into human health and dis-
ease and could provide novel DNA-based biomarkers for
detection and risk stratification of various human health
disorders. Such DNA based biomarkers are already enter-
ing clinical use for detection of various cancers including
prostate cancer [4].
Current methods for genome-wide DNA methylation
analysis differentiate between methylated and unmethy-
lated DNA on the basis of sodium bisulfite modification,
methylation-sensitive (e.g. R.HpaII) and -specific (e.g. R.
McrBcI) restriction enzymes, and/or affinity reagents spe-
cific for methylated DNA such as the anti-5meC antibody
or recombinant methyl-binding domain (MBD) polypep-
tides [5,6]. Among these, the affinity-based strategies are
particularly attractive because they are cost-effective, are
not limited to specific target sequences, generate a positive
signal for methylated DNA, and can be highly effective in
fractionating methylated DNA from unmethylated DNA.
In particular, the MBD approaches, pioneered by Adrian
Bird and colleagues [7,8], are highly effective because the
MBD polypeptides can recognize 5meC in double
stranded DNA unlike the currently available antibodies.
Even among the MBD polypeptides, just the MBD domain
of the human MBD2 protein (MBD2-MBD) has exqui-
sitely high affinity and specificity for 5meC, and previous
reports have used this reagent to sensitively and specifi-
cally detect methylated DNA from as few as 5 cell equiva-
lents [9].
An emerging strategy for analysis of DNA fractionated
by affinity-based enrichment has been to hybridize
enriched libraries to promoter [10-12], CpG island
[13-15], chromosome-wide [15], or genome-wide [16] til-
ing microarrays or to analyze by next generation sequen-
cing [17,18]. Here, we describe the use of an MBD-chip
approach (Figure 1A) to compare the chromosome-wide
DNA methylation patterns in LNCaP prostate cancer cells
and PrEC normal prostate epithelial cells. Using this infor-
mation, we make novel observations regarding cancer-
normal differences in methylation patterns in various bio-
logically meaningful genome compartments without bias
to promoter regions. This method uses MBD2-MBD
bound magnetic beads to specifically enrich for methylated
DNA fragments followed by processing, hybridization and
analysis with high-density, oligonucleotide tiling microar-
rays containing probes interrogating all non-repetitive
sequences on chromosomes 21 and 22 with an average
interval between probes of 10 base pairs (bp). We also pre-
sent novel analytical strategies to overcome challenges in
pre-processing and analysis of DNA methylation microar-
ray data and approaches for biological interpretation of
such data. These analyses revealed pervasive methylation
of both gene promoter and non-promoter regions in
cancer and normal cells. Focusing on the differentially
methylated regions between cancer and normal cells,
hypermethylated non-promoter regions include intragenic
and intergenic regions. The hypermethylated intragenic
regions were highly enriched for localization to exons and
intron-exon boundaries, suggesting a possible role in regu-
lation of alternative transcriptional start sites, exon usage
and/or splicing. The hypermethylated intergenic regions
showed a high degree of enrichment for conservation
across vertebrate species. Regardless of their regulatory
role, these intra- and intergenic hypermethylated regions,
in addition to the promoter hypermethylated regions,
could be used to distinguish prostate cancer from normal
prostate and therefore could serve as biomarkers for pros-
tate cancer detection.
Results
Development and refinement of MBD-Chip and
associated computational analyses
We previously showed that MBD2-MBD polypeptide-
bound magnetic beads could be used to efficiently and
quantitatively capture methylated DNA fragments [9].
To further characterize the binding properties of the
MBD2-MBD magnetic beads, we used human white
blood cell (WBC) genomic DNA known not to be
methylated at the GSTP1 promoter, and treated it with
the M.HhaI (5’-GCGC-3’ recognition sites) and/or M.
HpaII (5’-CCGG-3’ recognition sites) methyltransferases
or with M.SssI (5’-CG-3’ recognition sites) methyltrans-
ferase or mock (no enzyme) to produce genomic DNA
that contains 0, 6, 10, or 37 methylated CpGs within a
262 bp GSTP1 R.AluI fragment. Subjecting these R.AluI
digested DNAs to MBD2-MBD enrichment and quanti-
fying the amount of enriched GSTP1 promoter DNA by
real time PCR revealed that the degree of enrichment
was proportional to the number of methylated CpGs in
a nonlinear fashion (Figure 1B). Next, we assessed the
performance of the MBD2-MBD enrichment at two
gene promoters (HBB, GSTP1) with known methylation
patterns in LNCaP and PrEC cells [9,19]. The genomic
DNAs were either completely methylated with the M.
SssI methyltransferase or left untreated. These analyses
further confirmed that the MBD2-MBD enrichment
robustly captures densely methylated regions, but not
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Figure 1 Overview and pre-microarray performance of MBD-chip. A, Overview of MBD-chip. Genomic DNA is: i) fragmented (in this case
with restriction enzymes), ii) enriched for methylated DNA using MBD2-MBD-magnetic beads, and iii) amplified, fragmented, labeled and
hybridized to tiling microarrays. Comparison with a total input fraction allows identification of methylated regions. B, Degree of MBD2-MBD
enrichment is non-linearly proportional to the number of methylated CpGs. WBC DNA was methylated at 0, 6, 10 or 37 CpG sites within an R.
AluI restriction fragment within the GSTP1 promoter by treatment with M.HpaII +/- M.HhaI or with M.SssI or no enzymes. The degree of MBD2-
MBD enrichment compared to mock (no MBD control), as measured by qPCR, was related to the number of methylated CpGs. ND, not
detectable. C, The MBD-chip process enriches DNA with high density of methylated-CpGs. DNA from LNCaP and PrEC cells was completely
methylated with M.SssI or left untreated. MBD2-MBD enrichment at regions in HBB and GSTP1 promoters, as examined by qPCR, are shown. The
CpG density (Low, indicates < 5 CpGs per kbp and high indicates > 20 CpGs per kbp) and known degree of methylation (as determined by the
Infinium 27K DNA methylation platform for HBB (unpublished data; Yegnasubramanian S and Haffner MC, 2011) and by bisulfite sequencing for
GSTP1 [9]) are indicated. Schematics of each region are annotated with position of CpGs (vertical hashes), transcriptional start sites (yellow arrow),
and amplification primers (red arrows). The start and end positions are with respect to transcriptional start sites.
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Page 3 of 19regions lacking methylated CpG dinucleotides or regions
with very low density of CpG dinucleotides (Figure 1C).
To analyze chromosome-wide patterns of methylation,
we used an MBD-chip approach in which genomic
DNA from LNCaP and PrEC cells was first fragmented
and divided into a total input fraction and an enriched
methylated fraction. The enriched methylated fraction
was subjected to enrichment for methylated fragments
using MBD2-MBD bound magnetic beads while the
total input fraction was not subjected to enrichment.
Each fraction was then amplified by random-primed
PCR (R-PCR), fragmented further, end-labeled, and
hybridized to microarrays containing probes interrogat-
ing all non-repetitive sequences on human chromo-
somes 21 and 22 with an average inter-probe separation
of 10 bp [20]. Each sample was analyzed in duplicate
experiments.
We next explored pre-processing of the DNA methy-
lation microarray data to facilitate downstream analysis
of absolute and differential methylation in the LNCaP
and PrEC specimens. As with nearly all oligonucleotide
microarray platforms, the Affymetrix tiling arrays exhib-
ited strong probe-effects, in which different probes on
the tiling array have inherent differences in their beha-
vior even when the underlying biological signal is
known to be constant. Because the total input fraction
should theoretically have uniform biological signal
across all probes on the tiling arrays, we took a log-ratio
of the enriched fraction to the total input to correct for
these probe effects.
It is well known from chromatin immunoprecipitation
microarray (ChIP-chip) experiments that even after tak-
ing a log-ratio to the total input fraction, significant resi-
dual sequence-based effects can persist. In one popular
analytical approach called model-based analysis of tiling
arrays (MAT), it is assumed that the majority of genomic
regions should not be enriched, and data across all
probes is used to build a sequence-based model to
account for these residual sequence-based effects [21].
Unfortunately, a direct application of this method to the
methylation tiling array data may be suboptimal since it
may not be valid to assume that the majority of the gen-
ome is not methylated. However, it is known that in
adult somatic cells, DNA methylation is almost entirely
restricted to CpG dinucleotides [22]. This, combined
with our empirical observations that the MBD2-MBD
enrichment does not retain DNA fragments with very
low CpG density, allows us to make the assumption that
regions of the genome with very low CpG density should
not be enriched and that any signal arising from such
regions in the genome are due to spurious effects. There-
fore, to assess residual sequence-based effects, we defined
“null probes” as those interrogating regions of chromo-
somes 21 and 22 with extremely low CpG density (< 4
CpG’s per 1000 bp). No appreciable enrichment signal is
expected on these probes due to lack of CpGs. Interest-
ingly, we noted a strong residual probe-enrichment inter-
action effect in which the log-ratio steadily increased
with probe guanine and cytosine (GC) content (Addi-
tional File 1 panel A). Additionally, likely because the GC
content in probes interrogating proximal genomic seg-
ments is expected to be similar, we also observed a strong
positional autocorrelation in the data from these regions
(Additional File 1 panel B). We adjusted for this GC con-
tent bias by subtracting a baseline log-ratio for each GC
stratum estimated from the null probes as defined above.
This adjustment resulted in baseline normalization of the
samples with the log-ratio in unmethylated regions set to
zero and, interestingly, essentially eliminated the autocor-
relation in null probes (Additional File 1 panel B). To
improve stability, we next smoothed these adjusted log-
ratios by taking a running median across k = 7 consecu-
tive probes (since the tiling interval is 35 bp on average,
the smoothing window is ~250 bp, approximately equiva-
lent to the modal fragmentation size), where k is a
smoothing parameter. This smoothed adjusted log-ratio
demonstrated a distribution that highly resembled what
would be expected for an independent and identically
distributed normal distribution (Additional File 1 panel
C), thus facilitating straight-forward statistical inference.
Therefore, this simple within-sample procedure allowed
baseline normalization across samples, elimination of
spurious GC content based effects, elimination of posi-
tional autocorrelation, and the ability to assign statistical
significance to a given region. Additional File 2 panel A
shows the effects of our pre-processing approach for a
representative 15 kilobase pair (kbp) region of chromo-
some (Chr) 21 in LNCaP cells. Note that the final
adjusted smoothed log-ratios have attenuated many ques-
tionable signals seen in the raw and smoothed log-ratios
while preserving the signal at specific regions. The accu-
racy of the final adjusted smoothed log-ratios was con-
firmed by bisulfite sequencing of representative regions
(see Additional Files 2, 3 and 4 and figures referenced in
different sections below).
Using an empirical normal distribution defined using
the null probes, we could then calculate a Z-score for
each probe on the array. The Z-score represents the
number of standard deviations separating the smoothed
adjusted log-ratio of a probe from the median of the null
probes having the same GC content. Methylated regions
were defined as those regions in which the additive
Z-score across all probes within 250 bp windows was >4,
a n da tl e a s to n ep r o b eh a dZ>3 .W et h e nm e r g e da l l
windows separated by < 250 bp together and calculated
the additive Z-score of these merged regions and ranked
them by this Z-score in order to highlight larger regions
when the enrichment is otherwise similar. This resulted
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Page 4 of 19in identification of 3,827 and 1,674 methylated regions in
the LNCaP prostate cancer cells and PrEC normal pros-
tate cells respectively (see Additional File 5 for the top
300 regions identified in each cell type) with a false dis-
covery rate of < 5% for both cell lines. Setting the
smoothing parameter k to 5 or 9 and repeating the ana-
lyses showed that most of the candidate regions that
were longer than 200 bp overlapped with those found by
setting k = 7, with only 3.4% and 4.4% of all regions
being new (i.e. not found when k = 7) for k = 5 or k = 9
respectively. Therefore, since changing k did not result in
large differences, our choice of using k = 7 to correspond
to the modal fragment size appears to be well justified.
We also examined the effect of choosing different
Z-score thresholds. The Z-score cutoff is essentially a
tuning parameter that enabled a locus to be considered
for enrichment. A larger Z cut-off for single probes
requires a peak with higher amplititude. By lowering this
cutoff, more candidate regions would be considered as
potentially methylated. However, because an additive
Z - s t a t i s t i cf o rt h ee n t i r er e g i o ni su s e dt od e c l a r ef i n a l
enrichment, lowering the initial cutoff does not necessa-
rily mean more enriched regions. One possibility is that
adjacent regions are more likely to be merged into larger
regions with a more permissive probe Z-score cutoff. By
lowering the Z-score cut-off from 3 to 2.57 (representing
the theoretical 99.5 percentile), we see that we only
obtain a single new region that is longer than 200 bp
with a final Z-score for the region greater than 4. There-
fore, it appears that our choice of Z > 3 is a reasonable
cut-off to use. It is likely that the smoothing parameter k
and the Z-score threshold would need to be custom set
for different enrichment based methylation tiling array
applications, with the optimal values depending on the
resolution of the microarray platform and the modal
DNA fragment length.
We next carried out analyses to identify genes that were
only methylated in the LNCaP cells and not in the PrEC
c e l l s ,o rv i c ev e r s a .T od ot h i s ,w em e r g e do v e r l a p p i n g
methylated regions from each of these samples, and identi-
fied those merged regions that had an additive Z-score > 4
in on one sample and Z < 1 in the other sample, repre-
senting highly stringent criteria for differential methyla-
tion. This analysis resulted in identification of 163 regions
in LNCaP cells that were not methylated in PrEC cells (see
Additional File 6 for the top 50 hypermethylated regions
in LNCaP vs. PrEC). Interestingly, we identified only 7
regions from Chromosomes 21 and 22 that were methy-
lated in the PrEC cells that were not methylated in the
LNCaP prostate cancer cells using our highly stringent cri-
teria. This is in agreement with a previous report that used
an independent method for identification of hypomethy-
lated gene promoter CpG islands in prostate cell lines, in
which the majority of hypomethylated promoter CpG
islands arose from sex chromosomes and not from the
autosomal chromosomes [23].
We next carried out extensive bisulfite sequencing
experiments of regions that were identified as either
methylated or unmethylated to assess the accuracy of the
overall MBD-chip and analytical approaches. This
included sequencing analysis of a total of 419 independent
clones covering 22 genomic regions, spanning 446 CpG
dinucleotides, for a total of ~5,800 methylation measure-
ments at individual CpG dinucleotides. This analysis
revealed correct classification of the methylation status of
19 out of the 22 tested regions, showing the high accuracy
of our overall MBD-chip and analytical approaches (see
Additional Files 2, 3 and 4). Several of these bisulfite-
sequencing verifications will be discussed in more detail in
subsequent subsections. In summary, the MBD-chip and
associated analytical approaches can be used to accurately
identify methylated regions in an absolute sense within a
single sample and also to identify regions that are differen-
tially methylated between samples.
We next assessed whether the identified methylated
and differentially methylated regions had higher CpG
dinucleotide content than would be expected if the
regions were selected randomly from chromosomes 21
and 22. To do this, we first took the top 1200 identified
methylated regions (top 600 from each chromosome)
from each of the cell lines and created 500 simulated
data sets that were matched to these regions in size and
ensured that we only chose regions that had coverage
on the tiling microarrays. We also created such simu-
lated data sets for the top 50 (top 25 from each chromo-
some) regions that were identified as differentially
methylated in the LNCaP cells compared to the PrEC
cells. We could then compare the distribution of CpG
dinucleotide content and number of regions overlapping
CpG islands in these simulated data sets with these
parameters in our actual observed data. This analysis
showed that our identified methylated and differentially
methylated regions, as expected, had significantly higher
overlap with CpG islands and contained higher CpG
dinucleotide content than the randomly selected simu-
lated data sets (p << 0.002; see Additional File 7). These
simulated data sets could also be used for assessing
whether several other genomic annotations were
enriched in our observed dataset compared to what
would be expected by randomly choosing regions
matched for appropriate parameters, as discussed in
subsequent subsections.
Enrichment of DNA methylation in intragenic or gene-
proximal regions
We next carried out genomic annotation of the identi-
fied methylated and differentially methylated regions in
the LNCaP and PrEC cells. For LNCaP and PrEC cells,
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Page 5 of 1966 and 65 percent of methylated sequences respectively,
were located within 3 kbp of known genes with only 34
and 35 percent of sequences lying in distal intergenic
regions > 3 kbp of known genes (Table 1). There were
no notable differences in region lengths between gene-
associated and intergenic methylated regions within
each cell line (Additional File 8). However, the average
segment length of methylated regions in the LNCaP
cells were significantly greater than those in the PrEC
cells across all genome compartments examined. Exam-
ining regions that were hypermethylated in the LNCaP
cancer cell line compared to the PrEC, 73 percent were
located within 3 kbp of known genes.
Given the strong association of methylated regions with
intragenic or gene proximal compartments, we more clo-
sely examined the localization of methylated regions
within specific gene associated compartments. First, the
LNCaP and PrEC cells showed significantly greater-than-
expected enrichment for DNA methylation at 5’
upstream regions of genes (Figure 2A). Additionally, this
5’ upstream enrichment was even more pronounced in
regions that were identified as hypermethylated in the
LNCaP cells compared to the normal PrEC cells, consis-
tent with the well-known trend for promoter hyper-
methylation in prostate cancer cells [4]. Figure 2B-C
shows a representative hypermethylated 5’ gene upstream
region (ADAMTS1 gene) with the accompanying bisulfite
sequencing validation. This 5’ upstream methylation of
the ADAMTS1 gene was associated with gene silencing
since treatment of LNCaP cells with 5-aza-2’-deoxycyti-
d i n e( A Z A d C )r e s u l t e di n~ 1 5 - f o l di n d u c t i o no f
ADAMTS1 mRNA expression (Figure 2D).
Interestingly, DNA methylation was enriched at the
3’ downstream regions of genes in the LNCaP cells but
not the PrEC cells. Additionally, such 3’ downstream
regions were also enriched in regions that were hyper-
methylated in the LNCaP cells compared to the PrEC
cells (Figure 3A). A representative hypermethylated 3’
downstream gene region, in this case downstream of
the DSCR9 gene, along with the bisulfite sequencing
verification of this region, is shown in Figure 3B-C.
We can speculate that such 3’ downstream methylation
m a yb ei n v o l v e di nr e g u l a t i o n of antisense transcripts
[24], or in regulating transcriptional elongation or
termination.
The majority of the gene-associated methylated regions
and cancer differentially-methylated regions occurred in
intron sequences. These intronic DNA methylation events
were significantly enriched compared to what would be
expected by random chance in our observed methylated
region data sets for each of the cell lines (Figure 4A). To
examine this enrichment more closely, all introns were
scaled so that the position within each intron could be
represented as a fraction between 0 and 100%, with 0%
representing the start of the intron and 100% representing
the end of the intron. The average smoothed adjusted log-
ratio across all introns was plotted along this fractional
position within the intron (Figure 4B). This analysis
revealed a higher average DNA methylation signal towards
the ends of introns compared to the middle of the introns,
suggesting that much of the DNA methylation signals
occurring in introns spanned intron-exon junctions. In
further confirmation of this observation, we found that
there was a significantly greater than expected enrichment
of identified methylated and differentially methylated
regions for overlapping with exon sequences and intron-
exon boundaries specifically (Figure 4C-D). We can specu-
late that this DNA methylation and hypermethylation in
cancer cells at intron-exon boundaries may be involved in
suppression of alternative transcriptional start sites as has
been reported recently [25]. Another potential role is in
the regulation of splicing or exon usage. A recent report
implicated specific histone modifications in regulating
alternative splicing events [26]. We can speculate that
these intron-exon DNA methylation events may also be
involved in such regulation or in the establishment or
reinforcement of these histone modifications.
Methylated regions from intergenic sequences are highly
enriched for conserved bases
Although the majority of methylated and differentially
methylated regions were associated with intragenic or gene
proximal regions, a significant fraction of identified regions
occurred in distal intergenic sequences (see Table 1).
There are at least two major hypotheses for methylation
and differential methylation at these distal intergenic
regions: i) these regions may not have any major regulatory
role and may have become methylated spuriously with sub-
sequent passenger maintenance of the methylation pat-
terns, or ii) methylation/hypermethylation of these regions
Table 1 Characteristics of identified methylated and hypermethylated regions
Number of regions Total length
of regions (kbp)
% Gene
upstream
% Gene
downstream
% Exon % Intron % Intergenic
LNCaP 3827 1468.6 4.4 4.2 7.2 50.2 34
PrEC 1674 523.7 4.6 3 8.1 49.4 35
Hypermethylated
1 163 147.5 9.5 5.4 4.2 54.4 26.6
1, Regions that are hypermethylated in the LNCaP cells compared to the PrEC cells.
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Figure 2 Methylation of 5’ gene upstream regions. A, Methylated regions in LNCaP (left) and PrEC (middle) cells, and hypermethylated (right)
regions in LNCaP vs. PrEC cells are significantly enriched within 2 kbp upstream of transcriptional start sites. The expected probability
distribution for (hyper)methylated regions to overlap with 5’ gene upstream regions is shown (gray bars and blue line). The red line indicates the
observed fraction of base pairs overlapping 5’ gene upstream regions in our actual dataset. B, DNA methylation signals (smoothed adjusted log2
(M/T)) surrounding a representative 5’ gene upstream region hypermethylated in LNCaP compared to PrEC. Annotations include chromosome
coordinates (top), CpG density (number of CpGs in sliding 250 bp windows), Refseq genes, and CpG islands. The box indicates a region that was
verified by bisulfite sequencing. C, Bisulfite verification of a hypermethylated region (boxed region from panel (B)) upstream of ADAMTS1. Circles
represent position of CpGs. In the top line for each cell line the color of each circle represents the fraction of sequenced alleles that were
methylated at that CpG according to the color scale (bottom). Each subsequent line represents the methylation pattern for each sequenced
clone; black and white circles indicate methylated and unmethylated CpGs respectively. D, AZAdC induces re-expression of ADAMTS1 in LNCaP
cells. Expression of ADAMTS1 with respect to that of GAPDH was measured by real time RT-PCR in LNCaP cells treated with vehicle (DMSO) or 1
μM AZAdC for 3 or 7 days.
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Page 8 of 19may have a role in physiological regulation of gene expres-
sion and/or carcinogenesis. In support of a regulatory role
for several of these intergenic regions, we found that these
regions exhibited significant enrichment for overlap with
highly conserved sequences across many mammalian and
vertebrate species (indicated by high phastCons scores >
0.8; [27]) compared with what would be expected by ran-
dom chance (Figure 5A). Additionally, we found that the
methylated and differentially methylated regions had a
highly significant enrichment of conserved transcription
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Page 10 of 19factor binding sites (Figure 5B; [28]). Taken together, the
overlap with high conservation and conserved transcription
factor binding sites suggested that many of these regions
that were not close to known genes may actually control
transcription of unrecognized RNAs or distal genes.
T oe x a m i n et h i sm o r ec l o s e l y ,w ef o c u s e do no n e
representative region in chromosome 22, which in our
initial analyses using theU C S Ch g 1 5R e f s e qg e n o m e
annotations was identified as an intergenic region show-
ing hypermethylation in the LNCaP cells compared to
the PrEC cells in our microarray data (Figure 5C). This
hypermethylation was verified by bisulfite sequencing
experiments (Figure 5D). This region overlapped with an
area of high conservation as denoted by high phastcons
scores (Figure 5C). Interestingly, mapping this region to a
more recent annotation of the human genome (UCSC
hg18), we saw that a new pseudogene, called psiTPTE22,
was mapped and annotated just downstream of this
region (Figure 5C). A recent study also characterized the
expression of a human endogenous retrovirus related
gene (psiTPTE22-HERV) that mapped to this locus, and
showed that this gene was likely silenced by DNA methy-
lation of the upstream region in kidney tumors [29]. We
next examined whether the differential methylation
observed upstream of this pseudogene was involved in
controlling expression of this pseudogene in the LNCaP
and PrEC cells. Using primers specific for this gene, real
time reverse transcriptase polymerase chain reaction
(RT-PCR) analyses showed that PrEC cells, which lacked
methylation of the upstream region, showed expression
of psiTPTE22. In contrast, LNCaP cells, which showed a
high degree of methylation of this region, showed signifi-
cant underexpression of this gene compared to PrEC
cells. However, treatment of LNCaP cells with AZAdC
led to increased expression of psiTPTE22 (Figure 5E).
We speculate that, like the methylation upstream of the
psiTPTE22/HERV pseudogene, many of the other distal
intergenic methylated and differentially methylated
regions may also be involved in controlling transcription
of previously unrecognized transcripts. Consistent with
this, recent reports have suggested that up to 10-fold
more genomic sequence may give rise to transcripts than
is currently appreciated in genomic annotations [20].
If conserved intergenic regions showing hypermethyla-
tion in the LNCaP cells compared to PrEC cells have a
regulatory role and can contribute to carcinogenesis, we
would expect that such regions may show hypermethyla-
tion across a series of prostate cancer tissues compared
to matched normal tissues. To test this, we selected a
representative intergenic region that showed a high
degree of conservation across vertebrate/mammalian spe-
cies and for which we were able to readily design COM-
PARE-MS methylation assays. For this region, we
assessed the degree of methylation in 21 subject-matched
prostate tumor-normal pairs. Interestingly, this region
showed consistent hypermethylation in the majority of
the tumors compared to the matched normals, with a
mean increase in each tumor compared to its matched
normal of > 2-fold (p = 0.008; Additional File 9). The
high frequency of hypermethylation of this region across
the tumor-normal pairs suggests that such regions may
be contributing to human prostate carcinogenesis. How-
ever, we would note that given the fact that there was
some detectable methylation in the normal specimens for
this particular intergenic region, we would not prioritize
it highly for development as a biomarker for prostate
cancer detection.
Newly identified differentially methylated regions can
serve as prostate cancer biomarkers
DNA methylation alterations have emerged as highly sen-
sitive and specific biomarkers in many human cancers
[30]. We assessed whether the differentially methylated
regions identified in this study could be useful as DNA
methylation biomarkers for effectively distinguishing pros-
tate cancer from normal prostate. We selected representa-
tive regions that were differentially methylated between
the LNCaP and PrEC cells, including two regions that
were 5’ upstream of known genes (ADAMTS1 and
SCARF2), two regions that were 3’ downstream of known
genes (DSCR9 and C21orf57), and one region that was
intragenic within a known gene (HLCS). Using the COM-
PARE-MS methylation detection assay [9], we confirmed
that these regions were not methylated in the PrEC cells
and were highly methylated in the LNCaP cells as pre-
dicted by our microarray and bisulfite sequencing analyses.
Additionally, several other prostate cancer cell lines were
methylated at these regions, with every prostate cancer
cell line showing significant hypermethylation of at least
three of these regions (Figure 6A). We next carried for-
ward three of these regions (ADAMTS1_Up, SCARF2_Up,
and DSCR9_Down) for testing in DNA isolated from
tumor and paired adjacent normal tissues taken from men
who underwent radical retropubic prostatectomy for man-
agement of primary prostate cancer (we omitted C21orf57
and HLCS associated regions because these showed some
methylation in the WBC DNA and therefore may not
serve as ideal biomarkers in human tissues, which may be
heterogeneous in cell type; seeF i g u r e6 A ) .I n t e r e s t i n g l y ,
all three of these regions exhibited high frequency of
methylation in the tumor samples (76%, 90.5%, and 19%
for ADAMTS1_Up, SCARF2_Up,a n dDSCR9_Down
respectively) with very infrequent methylation in the
matched normal specimens (Figure 6B). Therefore, the
regions that were identified to be differentially methylated
in the LNCaP compared to PrEC cells as identified in this
study by our overall MBD-chip and associated computa-
tional approaches are likely to be highly enriched for
Yegnasubramanian et al. BMC Genomics 2011, 12:313
http://www.biomedcentral.com/1471-2164/12/313
Page 11 of 19effective DNA methylation biomarkers for prostate cancer
identification.
Discussion
In this study, we have developed, refined and applied an
MBD-chip approach along with accompanying computa-
tional analyses for comparison of chromosome-wide DNA
methylation patterns in prostate cancer cells with those in
normal prostate epithelial cells. We present several tech-
nological advances over previous affinity-enrichment
based DNA methylation profiling approaches. First, the
enrichment process has been streamlined and optimized
for fairly small amounts of input DNA (only 300 ng of
DNA were used for these studies). Second, compared to
antibody based approaches which require the generation
of single-stranded DNA for affinity enrichment of methy-
lated DNA, the MBD-based enrichment approach offers
the ability to enrich for methylated double-stranded DNA.
Third, among the MBD-based approaches for affinity
enrichment of methylated DNA, the fragment of the
MBD2 protein used in this study is highly streamlined
for binding methylated DNA with high affinity and selec-
tivity [9]. The high selectivity of the MBD2-MBD polypep-
tide for methylated DNA and the high density of the
oligonucleotide tiling microarrays covering all non-repeti-
tive regions of chromosomes 21 and 22 with an average
inter-probe spacing of ~10 bp allowed unbiased, high-
resolution, chromosome-wide mapping of DNA methyla-
tion in the LNCaP prostate cancer cell line and the PrEC
normal prostate epithelial cells in primary culture. Finally,
we have developed novel computational approaches for
analysis of affinity enrichment-based genome-wide DNA
methylation data that correct for sequence bias in the
methylation signal. The resulting methods greatly enhance
the specificity and accuracy of the DNA methylation calls.
These analytical methods were specifically optimized for
interpretation of DNA methylation tiling microarray data.
Knowing that DNA methylation occurs almost exclusively
at CpG dinucleotides in adult somatic human cells, and
that the MBD2-MBD polypeptide very selectively binds
CpG methylated DNA, we were able to define a set of null
probes that interrogate regions of the genome that contain
an extremely low CpG density that should never be
enriched. The signals arising from these probes allowed us
to identify and correct for sequence biases that led to
increased spurious signals in these regions. Additionally,
one theoretical advantage of high-density tiling microar-
rays is that, if we assume independence between signals
from adjacent probes, multiple consecutive probes exhibit-
ing enrichment would multiplicatively increase our confi-
dence that the overlying region was truly enriched.
However, in many cases of tiling array data, the assump-
tion of independence of adjacent probes is clearly not met
and we therefore cannot easily calculate the confidence of
signals arising in multiple consecutive or adjacent probes.
In our own data also, we saw that the raw smoothed log-
ratios from null probes were highly autocorrelated with
the smoothed log-ratios from adjacent probes. However,
correcting for the GC content sequence biases using the
null probes eliminated this autocorrelation, allowing us to
assume independence in signals arising from consecutive
null probes. The resulting analyses were highly accurate
for absolute methylation calls, with false discovery rates of
< 5% and concordance with bisulfite sequencing data
of ~90%.
In this study, we restricted analysis to absolute (qualita-
tive) DNA methylation calls because significant new com-
putational methods development is necessary for
quantitative analysis of DNA methylation from affinity-
enrichment based genome-wide DNA methylation data.
This is because deriving quantitative information regarding
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Figure 6 Hypermethylated regions in LNCaP compared to PrEC
cells can serve as biomarkers for prostate cancer. A, DNA
methylation at representative regions identified as hypermethylated
in LNCaP cells compared to PrEC cells was measured in prostate cell
lines using the COMPARE-MS assay as described previously [9]. The
extent of methylation at each region is color scaled from white to
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Page 12 of 19the fraction of input DNA that is methylated at a given
locus from affinity-enrichment based approaches is con-
founded by multiple issues that are independent of the
fraction of methylated input DNA fragments. First, the
degree of enrichment is clearly influenced by the density of
methylated CpGs around a given locus, and this appears to
show a non-linear dependence. Second, the degree of
enrichment is likely influenced by various sequence effects
and biases. These biases we have in large part been able to
isolate and adjust for in qualitative analyses (as described
in the manuscript), but significant further research is
required to understand how such parameters influence the
ability to quantitate methylation levels at a given locus in a
specific sample. Third, the degree of enrichment at a given
locus is influenced by the total amount of captured species
in a given sample. That is, because the same amount of
total DNA is hybridized (or sequenced) for each sample,
the degree of signal at a given region is influenced both by
the amount of methylation at that region and by the total
number of methylated molecules making up the enriched
sample. Unfortunately, it seems likely that each of these
parameters can influence the other parameters in a non-
linear and currently unpredictable fashion. In ongoing stu-
dies, we are developing methodologies to overcome these
issues in order to facilitate accurate quantitative estimates
of DNA methylation from enrichment-based genome-wide
DNA-methylation data. In the meanwhile, our accurate
approaches for qualitative assessment of DNA methylation
have allowed significant new biological insights into the dif-
ferences in chromosome-wide DNA methylation patterns
in a cancer/normal model system.
In the classically held view, DNA methylation patterns
in cancer cells differ from normal cells in at least two
major ways [31,32]. First, they often harbor hypomethyla-
tion of repetitive elements and of regions of the genome
with low CpG density. Our methods did not directly
interrogate this aspect of DNA methylation biology since
repetitive elements were excluded from the arrays to
avoid cross-hybridization signals and because our
method, like other restriction enzyme and enrichment
based genome-wide DNA methylation assays, cannot
robustly detect differential methylation in regions with
very low CpG density [5,6]. Second, cancer cells are
thought to become hypermethylated mostly in CpG
islands at the promoters of genes, resulting in epigenetic
silencing of those genes. Accordingly, the majority of
genome-wide DNA methylation assays have focused on
CpG islands and promoters using various types of micro-
array formats with probes that selectively interrogate
such regions. Here, we assessed whether DNA hyper-
methylation changes in cancer cells occur mostly in gene
promoter CpG islands by carrying out an unbiased
assessment of DNA methylation across all non-repetitive
regions of chromosomes 21 and 22 (without bias to
promoters, genes, or other annotations) in prostate can-
cer and normal prostate cells.
Annotation of the identified methylated regions revealed
a significant clustering of DNA methylation in gene-asso-
ciated compartments of the genome in both the cancer
and normal cells, and in regions found to be hypermethy-
lated in the cancer cells. We identified numerous 5’ gene
upstream regions that were methylated in the cancer and
normal cells, some of which were differentially methylated
in the cancer cells. For some of these regions, we con-
firmed that demethylation using a methyltranferase inhibi-
tor led to re-expression of the associated gene, suggesting
that methylation of these regions was indeed involved in
epigenetic silencing of the associated gene. Two of these
regions were confirmed to be novel biomarkers for pros-
tate cancer in an independent set of prostate cancer cell
lines and prostate cancer tissues.
Interestingly, we also found significant enrichment for
methylation greater than would be expected by random
chance for several other gene-associated genome compart-
ments. For instance, we found that methylation of 3’ gene
downstream regions was enriched to nearly the same
extent as 5’ gene upstream regions in the LNCaP prostate
cancer but not PrEC normal prostate cells, and was also
enriched in the cancer hypermethylated regions. Recent
reports have suggested that many genes may have anti-
sense transcripts that may be involved in the regulation of
the sense transcripts [24]. We speculate that methylation
of the 3’ downstream regions may be involved in the regu-
lation of such antisense transcripts. Another possibility is
that methylation of such regions is involved in regulating
transcriptional elongation/termination or transcript pro-
cessing such as polyadenylation. Further studies will be
required to understand the role of the 3’ gene downstream
methylation events.
Introns and exons also showed significant enrichment of
methylation in the cancer and normal cells. Interestingly,
exon sequences and intron-exon junctions showed an
extremely high degree of enrichment within methylated
regions in cancer and normal cells, as well as in hyper-
methylated regions in the cancer cells. Luco et al., recently
showed that histone methylation patterns occurring at
intron-exon boundaries can play a role in regulating alter-
native splicing of mRNA [26]. We speculate that DNA
methylation patterns may help to reinforce these histone
methylation patterns or may also be directly involved in
regulation of alternative splicing. Another recent report
has suggested that DNA methylation patterns occurring
within gene bodies may be involved in regulation of alter-
native transcriptional start sites [25]. To our knowledge,
neither of these or other previous reports compared gene
body methylation in cancer and normal cells. Our data
suggest that such gene body DNA methylation can
become abnormally increased in prostate cancer cells. We
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Page 13 of 19can speculate that cancer cells can take advantage of this
regulatory machinery to activate oncogenes or silence
tumor suppressors by dysregulating production of alterna-
tive transcripts and spliceoforms.
Although the majority of methylated regions over-
lapped with gene-associated genome compartments, a
significant fraction of regions (~30 - 40%) were distal
intergenic, occurring at least 3 kbp away from any known
genes. Several such distal intergenic regions showed
hypermethylation in the cancer cells compared to the
normal cells. Interestingly, these intergenic methylated
and cancer hypermethylated regions were significantly
enriched for a high degree of conservation across several
mammalian and vertebrate species, suggesting that there
are significant evolutionary pressures against changes at
these regions. We can speculate that these regions are
involved in long range regulation of genes. Another pos-
sibility is that some subset of these intergenic methylated
regions are involved in regulation of nearby transcripts
that are not yet annotated or known. Consistent with
both of these hypotheses, the genomic methylated
regions are highly enriched for conserved transcription
factor binding sites.
Regardless of the function of the cancer hypermethy-
lated regions, it is apparent that many of these have signifi-
cant potential in serving as DNA methylation biomarkers
of prostate cancer. Cancer hypermethylated regions from
different annotation categories (5’ gene upstream, 3’ gene
downstream, intergenic) were frequently methylated in
prostate cancer cell lines but not the normal prostate
epithelial cells. A few of these (regions associated with
ADAMTS1, SCARF2,a n dDSCR9)w e r et e s t e df u r t h e r ,a n d
in combination, showed ~100% sensitivity and ~85% spe-
cificity for prostate cancer compared to matched adjacent
benign tissues.
We envision several possibilities for application of the
methodologies presented here for cancer biomarker devel-
opment. For example, the MBD-enrichment based gen-
ome-wide DNA methylation approaches can be applied to
tumor-normal pairs from several subjects of a given cancer
type to assess whether there are any high-frequency DNA
methylation changes that can distinguish tumor vs. normal
tissue. Then, sensitive DNA methylation analytical techni-
ques, such as COMPARE-MS [9], real-time MSP [19] or
MethyLight [33], Methyl-BEAMing [34], etc., can be used
to measure a panel of these DNA methylation alterations
in blood, urine, stool, biopsies or other patient biomater-
ials. A different strategy, analogous to one that was
recently described [35], would involve development of per-
sonalized DNA methylation biomarkers. In this strategy,
for a given individual, technologies similar to those pre-
sented here would be applied to profile the genome-wide
DNA methylation patterns distinguishing the individual’s
tumor from their own normal tissues. These personalized
methylation alterations could then be followed in blood,
urine or other biospecimens using the various sensitive
DNA methylation techniques listed above to track
response to therapy, follow disease burden, etc. Of course,
such strategies will require significant testing prior to clini-
cal implementation.
The overall MBD-chip approach described here should
be broadly applicable to characterizing genome-wide DNA
methylation patterns and to identify novel DNA methyla-
tion biomarkers for various diseases. The MBD2-MBD
polypeptide is now commercially available as part of kits
for enriching methylated DNA marketed by different com-
panies (e.g. ClonTech, Invitrogen), and is therefore easily
accessible to the research community. Additionally, tiling
microarrays interrogating all non-repetitive regions of the
entire genome of multiple species, including humans, are
now available through various companies including Affy-
metrix, Nimblegen, and Agilent. Therefore, the methodol-
ogies presented here can be readily applied to analysis of
the entire human genome. Furthermore, these methods
should be easily adaptable to analysis with next generation
sequencing [17]. For instance, recent studies have demon-
strated that next generation sequencing platforms also
produce significant sequence biases in data produced by
their applications [36], including DNA methylation data
[18]. It has been shown that sequence biases and amplifi-
cation bias can affect affinity-enrichment based DNA
methylation data produced by next generation sequencing
platforms [18]. The general principle of using regions of
the genome with ultra-low CpG content to correct such
artifactual effects in DNA methylation data introduced by
technology platforms should be generally applicable.
Methods such as those presented here are poised to facili-
tate the thorough examination of DNA methylation pat-
terns genome-wide in health and disease.
Conclusions
We have developed and refined MBD-Chip and associated
computational methods for analysis of DNA methylation
using high-resolution oligonucleotide tiling microarrays.
These analyses were deployed to compare chromosome-
wide DNA methylation patterns in normal and malignant
prostate cells, revealing significant enrichment of DNA
methylation and hypermethylation of gene-proximal geno-
mic regions, including 5’-gene upstream regions, 3’-gene
downstream regions, and those spanning intron-exon
junctions. Interestingly, intergenic methylated and hyper-
methylated regions showed a significant enrichment for
harboring highly conserved sequences across vertebrate
species. Several of these newly identified cancer hyper-
methylated regions were highly effective as DNA methyla-
tion based biomarkers capable of sensitively and
specifically distinguishing malignant from normal prostate
tissues and cell lines.
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Cell lines, tissue specimens, treatments, and DNA/RNA
extraction
LNCaP and PrEC cells were grown and maintained as
described previously [19,23]. Fresh frozen blocks of
tumor and matched non-cancer containing tissues from
men that underwent radical prostatectomy for treatment
of clinically localized adenocarcinoma of the prostate
were obtained from the Brady Urological Institute Pros-
tate Specimen Repository at Johns Hopkins. These spe-
cimens ranged in Gleason score from 6 - 9, and the
pathological stage ranged from T2N0Mx to T3bN0Mx.
Microscopic tissue sections were stained by hematoxylin
and eosin (H&E) and examined to ensure purity of
tumor-containing and non-tumor containing regions.
Purity of tumor samples was estimated to be between
70-90% pure. Subsequent tissue sections were taken for
DNA isolation, and then additional H&E sections were
examined to ensure continuity of the diagnoses. Geno-
mic DNA was isolated from tissue specimens and cells
using the DNeasy kit (Qiagen) according to the manu-
facturer’s protocols. WBC DNA was purchased from
Novagen. Treatment of DNA samples with M.HhaI and/
or M.HpaII, and M.SssI DNA methyltransferases (NEB)
were carried out according to the manufacturer’s recom-
mended protocol. For DNA demethylation and gene re-
expression studies, LNCaP cells were treated every day
for up to one week with 1 μM AZAdC in DMSO or, as
a control, with an equivalent volume of DMSO carrier.
Cells were harvested by trypsinization at 3 and 7 days
and total RNA was isolated using the RNeasy kit (Qia-
gen) according to the manufacturer’s protocols.
MBD-Chip sample preparation
300 ng of genomic DNA samples were separated into
three fractions and each fraction was digested in a 10
μL reaction with either R.AluI (NEB), R.HaeIII (NEB),
or R.MseI (NEB) according to the manufacturer’s
recommendations. Splitting samples into three reactions
and digesting each reaction with one of three 4-base
recognition sequence restriction enzymes allowed frag-
mentation of DNA while maintaining high representa-
tion of genome sequences in fragments > 100 bp. The
three restriction digestion reactions were then pooled to
reconstitute the original sample. Half of this digested
sample was set aside and designated as “input control”.
The remaining half was designated as the “unknown
methylated fraction”.
The “unknown methylated fraction” was subjected to
enrichment for densely methylated DNA sequences by
capture with MBD2-MBD immobilized on magnetic
beads using a procedure similar to that used in COM-
PARE-MS as described previously [9]. Briefly, in a pre-
capture step, 2.5 μL of Protein G Magnetic Beads (NEB,
Beverly, MA) were gently shaken for 1 hour at room
temperature with 1 μg of PentaHis Antibody (Qiagen,
Valencia, CA), 160 nM MBD2-MBD-6His, and 200 ng
of an unmethylated self-ligated TOPO-TA plasmid
(Invitrogen, Carlsbad, CA), in 97.5 μL of BW Buffer(4%
glycerol, 1 mM MgCl2, 0.5 mM EDTA, 0.5 mM DTT,
50 mM NaCl, 10 mM Tris-HCl (pH 7.4), 0.2% Tween-
20, and 1X Complete EDTA-free Protease Inhibitor
cocktail). Unbound antibody and MBD polypeptides
were removed by immobilizing beads on a Magnetight
HT96 magnetic rack (Novagen, San Diego, CA) and
removing the supernatant. The methylated fraction sam-
ples were diluted in 100 μL of BW buffer and then incu-
bated with the protein G magnetic beads for 3 hours at
room temperature with gentle shaking. The beads were
then immobilized on the Magnetight HT96 rack and
washed five times with BW Buffer. After the final wash,
the bound methylated fraction DNA was eluted by add-
ing 20 μL of 1 mM Tris-HCl pH 8.0 and heating to
95°C for 15 minutes. The magnetic beads were again
immobilized on the Magnetight HT96 rack and the
supernatant containing the eluted methylated fraction
DNA was removed and stored until unbiased amplifica-
tion. Purified recombinant MBD2-MBD polypeptides
were produced as described previously [9].
The input controls and unknown reactions were sub-
jected to unbiased, whole-genome amplification via a
random-primed amplification (R-PCR) strategy as
described previously [37-40]. Briefly, DNA was subjected
to two successive one strand synthesis reactions using
Sequenase DNA polymerase (USB) and Primer A (5’-
GTTTCCCAGTCACGATCNNNNNNNNN), featuring
a degenerate 3’ end for random-primed polymerization
and a specific 5’ sequence. This reaction was then sub-
jected to 25 cycles of PCR amplification with Primer B
(5’-GTTTCCCAGTCACGATC). After verification of
robust amplification by 1% agarose gel electropheresis,
amplified products were purified with the Qiagen PCR
purification kit and quantified by standard UV absor-
bance spectrometry.
Whole genome amplified DNA was then subjected to
partial digestion for 6 min at 37°C with 5 Units of
DNAse I (Epicentre) in a 40 μL reaction containing 1x
One-Phor-All buffer (GE Healthcare). Fragmented DNA
was 3’-biotin end-labeled by incubation with 70 μMb i o -
tin-ddATP, 100 Units Terminal DNA Transferase (TdT;
Roche), 2.5 mM CoCl2, and 1x TdT buffer (Roche) in a
70 μL reaction. Labeled DNA was hybridized according
to the manufacturer’s instructions, to GeneChip
® Human
Chromosome 21/22 Tiling 1.0R Array Sets (Affymetrix)
consisting of 3 microarrays containing 25-mer oligonu-
cleotide probes that are tiled across all non-repetitive
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35 bp resolution (i.e. average distance between probes is
10 bp). Hybridization reactions and scanning were car-
ried out by the Johns Hopkins Microarray Core facility.
Each sample was analyzed in duplicate experiments.
Pre-processing and analysis of microarray data
Microarray data pre-processing and analysis were car-
ried out using R statistical programming language (R
Development Core Team, http://www.r-project.org) and
Bioconductor software [41], except where noted. Micro-
array probe sequences were mapped to the hg15 and
hg18 UCSC genome builds. A set of “null probes” was
defined as those probes that mapped to three different
long regions of chromosomes 21 and 22 with very low
CpG content of < 0.4%. For each sample, the mean log2
intensity on each probe between the duplicate experi-
ments was formed to calculate the log2 ratio between
the methylated (M) and the total input (T) fractions.
The probe effect of the log2 ratio was estimated from
null probes stratified by probe GC content as the med-
ian log ratio for each GC stratum. This estimated probe
effect was subtracted from the raw log-ratio for all
probes to form the adjusted log ratio. A running median
of this adjusted log2(M/T) ratio was calculated across a
sliding window of 7 adjacent probes and was taken as
the final pre-processed measure of methylation. For
each probe, a Z-score, calculated as the number of stan-
dard deviations from the median log2(M/T) of the null
probe bin with the same GC content, was determined.
All probes with Z-score > 3 were considered as poten-
tially enriched. All enriched probes within 250 bp of
proximity were merged to form enriched genomic seg-
ments and the sum of Z-scores in the segment was cal-
culated. All genomic segments with Z > 4 were
considered as significantly methylated. Since the
smoothed adjusted log2(M/T) in the null regions were
found to be approximately normally distributed, this Z-
score threshold corresponds to p < 3.2E-5. To estimate
false discovery rates, this analysis was performed on
replicate total input fractions in which the log2(Total
Inputreplicate1/Total Inputreplicate2) was used in place of
log2(M/T). The number of regions with Z > 4 in this
absolute null dataset was used to estimate the false dis-
covery rate for each sample. To identify differentially
methylated regions that were likely to be methylated in
one of the cell lines and show absence of methylation in
t h eo t h e r ,w ec o n s i d e r e da l lr e g i o n st h a tw e r ec o n s i d -
ered to be methylated in the LNCaP or PrEC samples
and merged overlapping regions together. For these
regions, we used the following highly stringent criteria
for identification of differentially methylated regions: i)
Z>4f o rt h er e g i o ni ne i t h e rt h eL N C a Po rP r E C
sample; ii) Z < 1 in the other sample; iii) region length
> 500 bp.
Analysis of whether methylated regions were enriched for
overlap with various genomic sequence annotations
CEAS software [42,43] was used to calculate the fraction
of identified methylated and differentially methylated
regions overlapping with various genome annotations
(introns, exons, 5’ gene upstream, 3’ gene downstream,
distal intergenic) and to carry out average profile analysis
of smoothed adjusted log2( M / T )v a l u e sa c r o s sa l ls h o r t
(842 - 2,715 bp) and long (2715 - 11,673 bp) intron
sequences represented on the microarrays. For analyses
examining whether methylated and differentially methy-
lated regions were enriched for various genome annota-
tions (CpG dinucleotide content, overlap with CpG
islands, bp overlapping 5’ gene upstream regions, 3’ gene
downstream regions, intron regions, exon regions, intron-
exon junctions, conserved intergenic sequences with
phastCons scores > 0.8, and overlap with conserved tran-
scription factor binding sites) we used annotations publicly
available through the UCSC genome browser database
[44] or the NCBI ftp server (ftp://ftp.ncbi.nih.gov/gen-
omes/MapView). We then took the top 1200 regions (top
600 from each of chr 21 and 22) for the LNCaP and PrEC
samples, and the top 50 differentially methylated regions
(top 25 from each of chr 21 and 22), and used a custom
Java (Sun Corporation) program to generate M = 500 in
silico data sets in which we randomly chose regions that
were matched to the regions in our experimental data set
for length and coverage on the microarrays. Randomly
chosen regions with the same length as the experimental
data set were generated in rank order (ranked by the stan-
dardized Z-statistic). Start sites for randomly selected
regions were constrained to start sites of probes repre-
sented on the microarrays to control for bias introduced
by probe design/selection on the microarrays. For each in
slico simulated dataset, region selections were constrained
to not overlap with previously selected regions. Each of
these datasets were then annotated for overlap with the
same annotations listed above. For each type of annota-
tion, we calculated the probability that the experimental
dataset was enriched for that type of annotation compared
to random chance as,p =N {random>experimental}/Q
where N{random > experimental} is the number of random
datasets with annotation measurement greater than that
in the experimental data set, and Q is the total number
of random datasets generated.
Bisulfite sequencing
Bisulfite sequencing was carried out as described pre-
viously [23]. Primers and associated annealing tempera-
tures are shown in Additional File 10.
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For COMPARE-MS analysis of DNA methylation at
newly identified cancer hypermethylated regions in pros-
tate cancer cell lines, tumor-normal paired tissues, and
reference samples, DNA samples were digested with R.
AluI and R.HhaI (NEB) and methylated fragments were
enriched and analyzed by real-time PCR as described
previously [9]. COMPARE-MS primers and correspond-
ing annealing temperatures for real time PCR are shown
in Additional File 10.
Quantitative RT-PCR
Quantitative RT-PCR analysis of ADAMTS1 and
GAPDH gene expression was carried out using Taqman
assays (Applied Biosystems) with procedures for reverse
transcription and real-time PCR as described previously
[45]. For the psiTPTE22 gene, SYBR green based real-
time RT-PCR was carried out using 400 nM forward
(5’-GTATGCTCTGACAACTATGAC) and reverse (5’-
GAGAGTGACATCCAGTAAGAC) primers, in 25 μL
reactions containing 1x SYBR Green RT-PCR reaction
mix (Biorad), 0.5 μL of iScript reverse transcriptase
(Biorad), and 50 ng total RNA. Cycling conditions were
55°C for 30 min, 95°C for 3 min, followed by 40 cycles
of 95°C for 30 sec, 58°C for 30 sec, and 72°C for 30 sec.
All real-time PCR analyses were performed on Biorad
iCycler thermal cyclers.
Additional material
Additional file 1: Pre-processing of MBD-chip data by correcting for
GC content-based probe-fraction interaction effects. A, The log2-ratio
of intensity from the methylated fraction to the total input (log2(M/T)) in
null probes (probes interrogating regions of chr 21 and 22 with very low
CpG density of <5 per 10 kbp) increases as a function of increasing
probe G+C content. B, The unadjusted log2(M/T) shows a strong
autocorrelation (left). Adjusting for G+C content nearly eliminates any
significant autocorrelation. C, A quantile-quantile (Q-Q) plot of observed
quantiles of the running median (smoothed) of adjusted log2(M/T) to
theoretical quantiles derived from a standard normal distribution, shows
that the smoothed adjusted log2(M/T) highly resembles what would be
expected for a running median of a standard normal distribution (red
diagonal line).
Additional file 2: Representative results and validation of the MBD-
chip pre-processing approach. A, The raw log2(M/T), smoothed log2(M/
T), and the smoothed adjusted log2(M/T) are shown for LNCaP cells for a
representative 15 kbp region on chr 22. The raw and smoothed log2(M/
T) appear to be high throughout the region. A running median of the
adjusted log2(M/T) attenuates the signal in most regions (e.g., boxed
region on the left) but maintains a high signal in a region upstream of
the ADAMTS1 gene (boxed region on the right). The shown region is
annotated with the chromosome coordinates (top), Refseq genes, and
CpG islands. B, Representative results of bisulfite sequencing experiments
verifying the accuracy of the smoothed adjusted log2(M/T) as a measure
of DNA methylation. Note that the boxed region on the left, which has
very low log2(M/T) signals from the microarrays (panel (A)), shows near
absence of methylation of the underlying CpG island, while the boxed
region on the right, which shows a relatively high log2(M/T) signal from
the microarrays (panel (A)), shows nearly complete methylation of the
underlying CpG island. Circles represent positions of CpGs. In the top
lines for each region, the color of each circle represents the fraction of
sequenced alleles that were methylated at that CpG according to the
color scale. Each subsequent line represents the methylation pattern for
each sequenced clone; black and white circles indicate methylated and
unmethylated CpGs respectively. This convention is used for all
subsequent bisulfite sequencing figures.
Additional file 3: Bisulfite sequencing verification data of
methylated regions identified by MBD-chip in the LNCaP and PrEC
samples. The “BSF data” columns show results from bisulfite sequencing
of an amplicon (chromosomal coordinates of each bisulfite sequencing
amplicon are shown above each region) within the region called by the
MBD-chip analysis. For each methylated region identified by the MBD-
chip analysis, the cell line, chromosome coordinates, and additive
standardized Z-score for each region are listed in the columns labeled
“MBD-chip data”. Conventions for bisulfite sequencing are the same as
those for Additional File 2 panel B.
Additional file 4: Bisulfite sequencing verification data of regions
that were identified as hypermethylated in the LNCaP compared to
the PrEC cells. Conventions are the same as those for Additional File 3.
Additional file 5: Top 150 methylated regions from each of
chromosomes 21 and 22 in LNCaP prostate cancer cells and PrEC
normal prostate epithelial cells.
Additional file 6: Top 25 regions from each of chromosomes 21 and
22 that are hypermethylated in LNCaP vs. PrEC.
Additional file 7: Identified methylated and hypermethylated
regions show a much higher CpG content and overlap with CpG
islands than would be expected by random chance. In each panel,
the distribution plot shows the expected probability (y-axis) due to
random chance of identifying regions with the indicated average fraction
of regions overlapping with CpG islands (left panels) or the indicated
number of CpGs per 1 kbp (right panels) as plotted on the x-axis. The
gray bars represent a non-parametric distribution for the expected
probabilities. The overlying blue line represents a best-fit normal
distribution of the expected probabilities. The vertical red line indicates
actual observed data.
Additional file 8: Segment lengths of methylated regions in LNCaP
cells are significantly longer than those of PrEC cells, but do not
differ significantly across different genome compartments within
each cell line. Shown are box-and-whisker plots representing the
distribution of segment lengths of methylated regions. The box
represents the 25
th to 75
th percentile, and the whiskers represent the 5
th
and 95
th percentiles. Red symbols indicate outliers.
Additional file 9: Frequent hypermethylation of a representative
conserved intergenic region. A, DNA methylation signals (smoothed
adjusted log2(M/T)) surrounding a representative intergenic region that
was identified to be hypermethylated in the LNCaP cells compared to
PrEC cells. The shown region is annotated with the chromosome
coordinates (top), CpG density (number of CpGs in sliding 250 bp
windows), and PhastCons scores. The boxed area represents the region
identified to be hypermethylated. Note that the region overlaps
sequences with high conservation as indicated by high PhastCons scores.
B, A waterfall plot of the extent of hypermethylation of the boxed region
from panel (A) in paired tumor-normal prostate tissues.
Additional file 10: Primers for bisulfite genomic sequencing,
COMPARE-MS, and analysis of MBD2-MBD enrichment.
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